Chronic pain is an enormous global health problem, often co-existing with sleep disruptions and depressive symptoms. There is a growing interest and a need in alternative treatments to pharmaceuticals that address the complexities of chronic pain. In this study we tested the efficacy of an oral spray supplement product, consisting of melatonin, L-Theanine, 5-Hydroxytryptophan and a proprietary herbal extract We assessed sleep quality, daytime sleepiness, pain, and depression. A retrospective study was performed by reviewing the charts of chronic pain patients from 40 to 65 years old in a chronic pain clinic who received an oral spray supplement (n=53) or no supplementation control group (n=39). The study aimed to assess changes in sleep quality, daytime sleepiness, depression, and pain via self-administered questionnaires using the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), Patient Health Questionnaire-9 (PHQ-9) and Brief Pain Inventory (BPI) resp. Between the control and oral spray supplement groups, a significant difference was identified for all four parameters assessed. There was a significant improvement in PSQI change between the two groups (p=0.001). This was also mirrored in the ESS (p=0.001), BPI (p=0.001), and PHQ9 (p=0.001). The most significant changes were seen between study onset and one-week thereafter. The novel formulation of ingredients used as a treatment in this study improved sleep, pain and depression in insomnia patients in the setting of chronic pain.